StreetSmart Live! Presents FansUnite Entertainment Inc on 11/30/2020. Learn More

Sector Expert: Alan Ridgeway

Paradigm Capital



Recent Quotes

"ONCY is well positioned as the market leader in virus-medicated cancer therapy."

— Alan Ridgeway, Paradigm Capital (10/1/13)
more >

"The second half of 2013 should be transformational for ONCY."

— Alan Ridgeway, Paradigm Capital (7/12/13)
more >

"We maintain our Buy rating on ONCY."

— Alan Ridgeway, Paradigm Capital (2/11/13)
more >

"ONC announced its first positive randomized data for Reolysin."

— Alan Ridgeway, Paradigm Capital (12/14/12)
more >

"ONC's Reolysin has the opportunity to be a transformational cancer therapeutic."

— Alan Ridgeway, Paradigm Capital (11/12/12)
more >

"ONC's prudent decision could lead to Reolysin use in a larger market."

— Alan Ridgeway, Paradigm Capital (9/13/12)
more >

"H2/12 should be transformational for ONC."

— Alan Ridgeway, Paradigm Capital (7/9/12)
more >

"ONC has a potential multibillion-dollar market opportunity with Reolysin."

— Alan Ridgeway, Paradigm Capital (6/20/12)
more >



Due to permission requirements, not all quotes are shown.